MX2021015056A - Compuesto de pirrolopirimidina y uso del mismo. - Google Patents

Compuesto de pirrolopirimidina y uso del mismo.

Info

Publication number
MX2021015056A
MX2021015056A MX2021015056A MX2021015056A MX2021015056A MX 2021015056 A MX2021015056 A MX 2021015056A MX 2021015056 A MX2021015056 A MX 2021015056A MX 2021015056 A MX2021015056 A MX 2021015056A MX 2021015056 A MX2021015056 A MX 2021015056A
Authority
MX
Mexico
Prior art keywords
pyrrolopyrimidine compound
pyrrolopyrimidine
relates
jak1
jak2
Prior art date
Application number
MX2021015056A
Other languages
English (en)
Inventor
Wenyuan Qian
Changqing Wei
Shuhui Chen
Guoping Hu
Jian Li
Original Assignee
Guangzhou Joyo Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Joyo Pharmatech Co Ltd filed Critical Guangzhou Joyo Pharmatech Co Ltd
Publication of MX2021015056A publication Critical patent/MX2021015056A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

La presente invención se refiere a un compuesto de pirrolopirimidina usado como un inhibidor de JAK, y el uso del mismo en la preparación de un fármaco para tratar una enfermedad asociada con JAK1 y/o JAK2, y específicamente se refiere a un compuesto representado por fórmula (I), un isómero del mismo o una sal farmacéuticamente aceptable del mismo. (ver Fórmula).
MX2021015056A 2019-06-05 2020-06-05 Compuesto de pirrolopirimidina y uso del mismo. MX2021015056A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910487056 2019-06-05
PCT/CN2020/094534 WO2020244614A1 (zh) 2019-06-05 2020-06-05 吡咯并嘧啶类化合物及其应用

Publications (1)

Publication Number Publication Date
MX2021015056A true MX2021015056A (es) 2022-01-18

Family

ID=73653145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015056A MX2021015056A (es) 2019-06-05 2020-06-05 Compuesto de pirrolopirimidina y uso del mismo.

Country Status (9)

Country Link
US (1) US20220227788A1 (es)
EP (1) EP3981769A4 (es)
JP (1) JP7261428B2 (es)
KR (1) KR20220017995A (es)
CN (1) CN113939514B (es)
AU (1) AU2020288567B2 (es)
CA (1) CA3140467C (es)
MX (1) MX2021015056A (es)
WO (1) WO2020244614A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115124526B (zh) * 2020-12-04 2024-01-30 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物中间体及其制备方法
CN113372366B (zh) * 2020-12-04 2022-08-30 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的盐、其晶型及其应用
CN114591333B (zh) * 2020-12-04 2023-08-01 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法
WO2022242768A1 (zh) * 2021-05-21 2022-11-24 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的应用
WO2022247885A1 (zh) * 2021-05-26 2022-12-01 正大天晴药业集团股份有限公司 三并杂环类化合物的结晶和盐及其应用
CN114432317A (zh) * 2021-05-31 2022-05-06 广州嘉越医药科技有限公司 吡咯并嘧啶类化合物的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4078074B2 (ja) * 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ［２，３−ｄ］ピリミジン化合物
US20130040933A1 (en) * 2010-04-27 2013-02-14 Brandon Cash Azaindoles as janus kinase inhibitors
WO2013085802A1 (en) * 2011-12-06 2013-06-13 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
MX356401B (es) * 2011-12-12 2018-05-21 Dr Reddys Laboratories Ltd Pirazol[1,5-a]piridina sustituida como inhibidores de la cinasa del receptor de tropomiosina (trk).
KR101864561B1 (ko) * 2015-01-20 2018-06-04 우시 포춘 파마슈티컬 컴퍼니 리미티드 Jak 억제제
JP6564473B2 (ja) * 2015-05-29 2019-08-21 无▲錫▼福祈制▲薬▼有限公司Ｗｕｘｉ Ｆｏｒｔｕｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ Ｊａｎｕｓキナーゼ阻害剤
JP2018199623A (ja) * 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
CN107805259A (zh) * 2017-10-31 2018-03-16 无锡福祈制药有限公司 一种吡咯并嘧啶类化合物
CN107652308A (zh) * 2017-10-31 2018-02-02 无锡福祈制药有限公司 一种Janus激酶3抑制剂

Also Published As

Publication number Publication date
EP3981769A1 (en) 2022-04-13
KR20220017995A (ko) 2022-02-14
CN113939514A (zh) 2022-01-14
JP7261428B2 (ja) 2023-04-20
EP3981769A4 (en) 2023-07-19
CA3140467C (en) 2023-08-01
WO2020244614A1 (zh) 2020-12-10
US20220227788A1 (en) 2022-07-21
AU2020288567B2 (en) 2023-06-15
AU2020288567A8 (en) 2023-02-09
CA3140467A1 (en) 2020-12-10
AU2020288567A1 (en) 2022-02-03
JP2022535838A (ja) 2022-08-10
CN113939514B (zh) 2022-12-27

Similar Documents

Publication Publication Date Title
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
MX2021010242A (es) Compuesto inhibidor de jak y uso del mismo.
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201791576A1 (ru) Ингибитор jak
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
EA202193015A1 (ru) Ингибиторы cdk
CR20220251A (es) Nuevos derivados de metilquinazolinona
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2021012105A (es) Compuestos de pirrol.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2022013273A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus metodos de uso.
EA202190398A1 (ru) Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4
MX2022005951A (es) Compuestos de pirrolotriazina que actuan como inhibidor de mnk.
PH12020551117A1 (en) Compositions for preventing or treating uveitis